{"id":"ar101-peanut-protein-capsule","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal symptoms"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AR101 is an oral immunotherapy that uses a gradual exposure approach to increase tolerance to peanut protein. This is achieved by administering increasing doses of peanut protein to patients over time, allowing their immune systems to adapt and reduce their allergic response.","oneSentence":"AR101 works by desensitizing the immune system to peanut protein, allowing individuals with peanut allergies to safely consume peanuts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:00.407Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peanut allergy"}]},"trialDetails":[{"nctId":"NCT03682770","phase":"PHASE2","title":"Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-10-03","conditions":"Peanut Allergy","enrollment":148},{"nctId":"NCT03736447","phase":"PHASE3","title":"Peanut Oral Immunotherapy Study of Early Intervention for Desensitization","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2018-12-27","conditions":"Peanut Allergy","enrollment":146},{"nctId":"NCT02635776","phase":"PHASE3","title":"Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2015-12-22","conditions":"Peanut Allergy","enrollment":555},{"nctId":"NCT01987817","phase":"PHASE2","title":"Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2014-02-06","conditions":"Peanut Allergy","enrollment":56},{"nctId":"NCT02198664","phase":"PHASE2","title":"Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2014-08-27","conditions":"Peanut Allergy","enrollment":47},{"nctId":"NCT03126227","phase":"PHASE3","title":"Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2017-05-08","conditions":"Peanut Allergy","enrollment":506},{"nctId":"NCT03201003","phase":"PHASE3","title":"ARTEMIS Peanut Allergy In Children","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2017-06-12","conditions":"Peanut Allergy","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AR101 - Peanut protein capsule","genericName":"AR101 - Peanut protein capsule","companyName":"Aimmune Therapeutics, Inc.","companyId":"aimmune-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AR101 works by desensitizing the immune system to peanut protein, allowing individuals with peanut allergies to safely consume peanuts. Used for Peanut allergy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}